Among the participants, 45 patients were eligible for assessing tumor response. 8 patients achieved partial response as their best overall response, resulting in an ORR of 17.8%. The disease control rate (DCR) was 60.0%. Median progression-free survival (mPFS) was 2.9 months....In this phase II trial, nivolumab demonstrated moderate efficacy and manageable toxicity in patients with solid cancer harboring DDR gene mutations.